Company intelligence / Profile preview
General Biologicals Corporation
- Ownership
- Private
- Development stage
- Other
Overview
GBC is a leading Taiwan-based developer of in vitro diagnostic devices and reagents with a global presence. Its CLIA systems are commercially available in over 40 countries. The company’s lead therapeutic candidate, the antimicrobial peptide P113 for oral candidiasis and related indications, has completed a promising Phase IIb clinical trial. GBC continues to expand its portfolio into precision medicine, digital health services, liquid biopsy technologies, and biologics manufacturing.
- Therapeutic areas
- OncologyInfectious DiseasesEndocrinologyGastroenterologyWomen's Health
- Modalities
- Diagnostic deviceChemiluminescent immunoassay (CLIA)Real-time PCR kitPeptide (for P113 antimicrobial peptide drug)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on General Biologicals Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on General Biologicals Corporation.